Sanjivani Paranteral Ltd. · BSE:SANJIVIN
Sanjivani Paranteral — Q1 FY26 Earnings Presentation
35 slides from Sanjivani Paranteral's earnings presentation, Aug 12, 2025
Slide 1: Cover letter to BSE for Investor Presentation
Date: 12th August, 2025 To, Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 531569 Sub: Investor Presentation for the First Quarter ended June 30, 2025. Dear Sir/ Madam, Please find enclosed herewith Investor Presentation of Sanjiva
Slide 2: Investor Presentation Q1 FY26
INVESTOR PRESENTATION Q1 FY26
Slide 3: Table of Contents
04 07 13 Market Overview About The Company Manufacturing Facilities 16 18 Company’s Segment & 22 CDMO Key Clients Global Footprint Revenue Mix Table of Contents 24 28 Financials 33 Stock Information Product Portfolio
Slide 4: Key Financial Highlights
Key Financial Highlights Q1 FY26 Revenue from Operations EBITDA* PAT Domestic & Export (up 8.9% Y-o-Y) (up by 10.8% Y-o-Y) (up by 1.0% Y-o-Y) (share in revenue) INR 178.9 mn INR 26.8 mn INR 17.3 mn 26.3% & 73.7% *EBITDA: includes other income Investor Presentation Q1 FY26 www.sanjivani.co.in 3
Slide 5: Market Overview
SANJIVANI PARANTERAL LTD MARKET OVERVIEW
Slide 6: Global Medicine Market
Global Medicine Market Use of medicines region wise, Defined Daily Doses (DDD) CAGR Country Name/Year 2018 2019 2020 2021 2022 2023 2024E 2025E 2026E 2027E 2028E 2024-2028 Asia-Pacific 451 461 477 507 547 538 559 580 598 618 637 3.4% Latin America 342 357 438 447 448 461 473 484 489 496 506 1.9% Wes
Slide 7: Global Medicine Market
Global Medicine Market Defined Daily Doses Global use of Global spending (DDD) in billions medicines on medicine 814 28% 73% [VALUE ] [VALUE ] [VALUE ] 2018 2028 2018 2028 2018 2028 Source: IQVIA Institute, Dec 2023. Investor Presentation Q1 FY26 www.sanjivani.co.in 6
Slide 8: About the Company
PARANTERAL LTD ry SANJIVANI ABOUT THE COMPANY
Slide 9: About Us
About Us Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product area
Slide 10: Significant Milestones of Sanjivani Paranteral Ltd.
Significant Milestones of Sanjivani Paranteral Ltd. 2009 2023 Dehradun 1. Entered into a Plant JV with Alevia Healthcare S.R.O in Prague in May’23 2. Entered into a JV with 1. Initial Hindustan commercial Achieved Antibiotics Ltd batches started milestone of in August’23 in Prague 1. Navi Mumbai add
Slide 11: Vision, Values, Mission
Vision of the Company VISION To be one of India’s best research-based pharmaceutical companies, through focus on quality and customer satisfaction. VALUES To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & tea
Slide 12: Sanjivani Paranteral's Competitive Advantage
Sanjivani Paranteral’s Competitive Advantage We have a compact and highly Our long-standing presence in the adaptable presence in India, industry has established us as a allowing us to be exceptionally respected leader, making us a nimble and agile preferred partner for top talent and reputable supp
Slide 13: Experienced Management
Experienced Management Mr. Ashwani Khemka Mrs. Mrunmai Sarvankar Mr. Srivardhan Khemka Chairman & Managing Director Director Executive Director Mr. Abhay Shah Ms. Monika A. Singhania Mr. Pritesh Jain Independent Director Independent Director Chief Financial Officer Investor Presentation Q1 FY26 www.
Slide 14: Manufacturing Facilities
SANJIVANI PARANTERAL LTD MANUFACTURING FACILITIES
Slide 15: Manufacturing Plant – Alevia HealthCare, Czech Republic
Manufacturing Plant – Alevia HealthCare, Czech Republic Investor Presentation Q1 FY26 www.sanjivani.co.in 14
Slide 16: IV Manufacturing Plant – SPL Infusion Private Limited, Pune
IV Manufacturing Plant – SPL Infusion Private Limited, Pune Investor Presentation Q1 FY26 www.sanjivani.co.in 15
Slide 17: CDMO Key Clients
SANJIVANI PARANTERAL LTD CDMO KEY CLIENTS
Slide 18: CDMO Key Clients
CDMO Key Clients Injectables Oral & Nutraceuticals Investor Presentation Q1 FY26 www.sanjivani.co.in 17
Slide 19: Company's Segment & Revenue Mix
COMPANY’S SEGMENT & REVENUE MIX
Slide 20: Product Category Mix (%)
Product Category Mix (%) Q1 FY26 Q1 FY25 0.4% 2.4% 37.2% 49.3% 50.2% 60.4% Injectables Tablets Nutraceuticals Injectables Tablets Nutraceuticals Investor Presentation Q1 FY26 www.sanjivani.co.in 19
Slide 21: Geographical Mix (%)
Geographical Mix (%) Q1 FY26 Q1 FY25 12.8% 26.3% 73.7% 87.2% Domestic Exports Domestic Exports Investor Presentation Q1 FY26 www.sanjivani.co.in 20
Slide 22: Region-wise Mix (%)
Region-wise Mix (%) Q1 FY26 Q1 FY25 4.5% 15.6% 23.8% 12.8% 45.5% 71.6% 26.3% Middle East & Africa India & Subcontinent Middle East & Africa India & Subcontinent Latin America Latin America CIS Countries Investor Presentation Q1 FY26 www.sanjivani.co.in 21
Slide 23: Global Footprint
SANJIVANI PARANTERAL LTD GLOBAL FOOTPRINT
Slide 24: Global Footprint
Global Footprint Prague CIS Countries Dehradun & India Navi Mumbai Central America Latin Pune America Dehradun, Navi Mumbai, Pune & Prague Investor Presentation Q1 FY26 www.sanjivani.co.in 23
Slide 25: Product Portfolio
SANJIVANI PARANTERAL LTD , —- a = SS a PRODUCT PORTFOLIO ; r| = |
Slide 26: Product Portfolio
Product Portfolio Investor Presentation Q1 FY26 www.sanjivani.co.in 25
Slide 27: Product Portfolio
Product Portfolio Urologics Anesthetics Anesthetics Anti Anti Thyroid Convulsants Agent Anti Anti Anti Anti Anti Anti-lepemic Anti Fungal Emetics Depressants Histamines Diabetic Agent Fibrinolytics Anti-bacterials Anti-spasmodic Anti Vitamin Skeletal Analgesic & Hypertensive Agent Supplement Muscle
Slide 28: Product Portfolio
Product Portfolio Non-opioid Antacids Antiseptics Nsaids Corticosteroids Analgesics Diuretics Immunosupress Narcotic Hormone Topical Anti Anxiety ants Corticosteroids Antibiotic Antipsychotic Anti Viral Narcotics Anti- Muscle Relaxant Investor Presentation Q1 FY26 www.sanjivani.co.in 27
Slide 29: Financials
ry SANJIVANI PARANTERAL LTD FINANCIALS
Slide 30: Segment-wise Revenue
Segment-wise Revenue (Injectables, Oral & Nutraceuticals) INR Mn. INJECTABLES ORALS 130.8 99.3 88.2 89.9 61.1 49.1 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 NUTRACEUTICALS 4.0 1.9 0.8 Q1FY25 Q4FY25 Q1FY26 Investor Presentation Q1 FY26 www.sanjivani.co.in 29
Slide 31: Quarterly Financials
Quarterly Financials Revenue, EBITDA & Margin, PAT & Margin INR Mn. REVENUE* EBITDA** & EBITDA Margin 181 182 179 14.7% 16.5% 16.7% 174 15.0% [VALUE] 164 24 32 29 30 27 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 PBT & PBT Margin PAT & PAT Margin 13.8% 14.2% 14.3% 12.8% [VA
Slide 32: Q1 FY26 Profit & Loss Statement
Q1 FY26 Profit & Loss Statement INR Mn. Particulars Q1 FY26 Q1 FY25 YoY% Q4 FY25 QoQ% Revenue From Operations 178.9 164.4 8.9% 181.8 -1.6% Other Income 0.4 0.9 -58.1% 4.3 -91.6% Total Income 179.3 165.2 8.5% 186.1 -3.7% COGS 111.1 102.6 8.3% 93.9 18.3% Gross Profit 68.1 62.6 8.8% 92.2 -26.1% Gross M
Slide 33: Long Term Growth Drivers
Long Term Growth Drivers Expand Product Strategic partnerships Portfolio & Collaborations 1 2 3 4 Therapeutic Expand into New Geographies Diversification Investor Presentation Q1 FY26 www.sanjivani.co.in 32
Slide 34: Stock Information
Stock Information Shareholding Pattern as on 30th June 2025 Stock Information (as on 30th June 2025) Market Cap. (in mn) 2552 28.9 Stock Price 214.8 38.9 6.2 52 Week (High / Low) 397 / 206 18.2 7.9 BSE – Symbol 531569 Free Float (No. of Shares) 84,51,239 Promoter Institutions HNI Corporate Bodies Re
Slide 35: Thank You
THANK YOU Sanjivani Paranteral Limited 205, P.N.Kothari Industrial Estate, L.B.S. Marg Bhandup (W), Mumbai- 400078, India. Ph: +91-22-20812600 / 25620515 Email: [email protected]